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Abstract
Solitary fibrous tumor (SFT) is a rare neoplasm composed of mesenchymal-derived spindle cells. Although SFT
occurs anywhere in the body, they most frequently affects the thoracic region. Here, we reported an extremely rare
case of an extrathoracic SFT occurring primarily in the kidney. To our knowledge, little information has been
described on the immunohistochemistry (IHC) and genetics of renal SFT.
A 41-year old Japanese female came to our hospital for further examination of a left kidney mass detected
incidentally with ultrasound. Extensive investigation of the tumor, including physical, laboratory, and image
examinations led to a clinical diagnosis of renal cancer (cT1aN0M0), which were in most parts imbedded in the
lower polar parenchyma. The patient underwent laparoscopic radical nephrectomy. The mass was diagnosed
pathologically as SFT originating from the kidney, but not as renal carcinoma. Microscopically, the tumor was
composed of spindle-shape cells distributed variably in dense collagenous stroma and had a focal
hemangiopericytomatous staghorn-like vascular pattern. Mitotic figures, atypical structures, necrosis and
hemorrhage were not identified. No adjuvant therapies were given postoperatively. The patient has been free of
tumor recurrence for 25 months since the surgery. IHC revealed that the tumor diffusely expressed CD34, CD99,
Bcl2, PAX8, NAB2, STAT6, and GRIA2. The tumor stained negatively for desmin, S-100, c-Kit, CK-AE1/AE3, CDK4 and
MDM2. A NAB2-SATA6 gene fusion was detected in tumor cells by reverse transcription-polymerase chain reaction,
direct sequencing, and an in situ proximity ligation brightfield assay. The gene fusion occurred as an 831 bp
truncation of exon 2 in NAB2 connected to the beginning of exon 3 in STAT6. We have reported a case of GRIA2
and PAX8-positive SFT occurring primarily in the kidney with such NAB2-STAT6 gene fusion for the first time. Diffuse
expression of PAX8 in the tumor might present with a renal origin. Reportedly, benign histology of SFT cannot
necessarily predict favorable clinical prognosis. Genetic alterations recently identified in SFT could possibly refer to
risk stratification for tumor recurrence. However, malignant preponderance of extrathoracic SFT over thoracic SFT
remains unexplained so far. Long-term follow-up after surgery should be performed in the present case.
Background
A solitary fibrous tumor (SFT) is a rare spindle cell
neoplasm originating from mesenchymal cells [1]. It was
first depicted in the pleura of the lung by Klemperer et
al. [2] in 1931. To date, SFTs have been reported in
various locations other than the pleura, including the
meninges, orbit, neck, nose, paranasal cavity, thyroid,
mediastinum, adrenal gland, liver, pancreas, retroperito-
neum, spermatic cord, skin, extremities, uterine cervix,
prostate, urinary bladder and kidney [3–5]. Among these
affected sites, renal SFT, first reported by Gelb et al. [6]
in 1996, is very rare. Approximately only 50 cases have
been described in the literature [7]. Microscopy and im-
munohistochemistry (IHC) of surgically resected or bi-
opsied tumor specimens is essential for SFT diagnosis,
as imaging modalities, including ultrasonography (USG),
computed tomography (CT) and magnetic resonance
imaging are unable to definitively differentiate SFT from
renal cell carcinoma (RCC) in most cases [8, 7]. Al-
though SFT is generally regarded as a benign tumor, up
to 10 % of extrapleural SFTs exhibit malignant behavior,
such invasion, recurrence, or distant metastasis [9–11].
SFT in the kidney is mostly benign but has malignant
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potential. Recently, there has been an increase in the
number of reports of malignant SFT, including metasta-
sis to lymph nodes [12], lung [10, 13, 14], liver [13, 14],
pancreas [11] and bone [15, 16], local recurrence [17, 3],
peritoneal implantation [3], and invasion to renal vein
[18]. Microscopically, the diagnostic criteria for malig-
nant SFT is the presence of increased cellularity with
crowded and overlapping nuclei, pleomorphism, necrosis
and hemorrhage, increased mitotic activity more than
four mitoses per ten high power fields (HPFs) [19, 8, 7].
However, some SFT patients without the malignant fea-
tures in microscopy presented with distant metastasis
[13, 14] and local invasion [18], suggesting that non-
malignant histology in SFT could not necessarily predict
benign behavior and favorable prognosis in clinical
practice.
Recently, NAB2-STAT6 gene fusions have been re-
ported in SFT [20–22]. Variations of NAB2-STAT6 gene
fusions could affect the clinical features, histology, and
prognosis of SFT [23, 24]. IHC of the diagnostic markers
STAT6 and GRIA2 would be important in differentiating
SFT from other soft tissue tumors [4, 5, 25, 26]. To our
knowledge, however, genetic and IHC analyses have only
been performed using tissue specimens from SFTs in
areas of the body other than the kidney, possibly because
renal SFT is extremely rare. In the present paper, we re-
port a patient who underwent radical nephrectomy for
treatment of cT1a RCC, which was postoperatively diag-
nosed by pathology as renal SFT with non-malignant na-
ture. NAB2-STAT6 gene fusions and IHC with anti-




A 41-year-old Japanese woman visited our institution for
further examination of a left renal mass with a diameter
of 3.3 cm detected incidentally by abdominal USG at a
municipal health workup for citizens 2 months prior.
She had been asymptomatic without any history of local
discomfort, hematuria, fever, sweat, or weight loss. Her
past and family histories were unremarkable, except that
she had taken oral contraceptives regularly for 10 years.
She was a never-smoker.
In a physical examination, the patient was normoten-
sive and not obese, with a height of 156.3 cm and weight
of 49.5 kg. Laboratory tests, including blood cell counts,
biochemistry, C-reactive protein, and urinalysis, showed
unremarkable results. A solid, well-demarcated, and het-
erogeneous mass lesion was observed in the lower pole
of the left kidney by USG, accompanied by arterial sig-
nals of blood flow within the tumor on color-Doppler
ultrasound (Fig. 1a). Plain CT of the tumor showed a
faintly higher attenuation than the outer parenchyma of
the left kidney (Fig. 1b). The tumor, mostly endophylic
in the renal parenchyma, measured 38.0 × 37.5 ×
33.6 mm in size in contrast-enhanced CT. Intratumoral
serpentine blood vessels were noted in the hypoen-
hanced tumor tissue in the arterial phase of dynamic CT
(Fig. 1c). Subsequently well-enhanced, the tumor showed
early washout of contrast media in the delayed phase
(Fig. 1d). There was no evidence of local invasion to the
adjacent tissues or metastasis to local lymph nodes or
distant organs in CT of the chest, abdomen, and pelvis.
Preoperatively, the patient was diagnosed with pap-
illary type I or chromophobe RCC at clinical stage I
(cT1aN0M0). The R.E.N.A.L. nephrometry score was
1 + 2 + 3 + p + 1 = 7p for R, E, N, A and L points, re-
spectively, showing moderate complexity of the tumor
mass [27, 28]. Endophylic lesions in the kidney are gener-
ally considered to be more challenging to surgical resection
than exophylic ones [28]. The patient consequently under-
went laparoscopic left radical nephrectomy. The postoper-
ative course was not eventful. No adjuvant treatment was
administered after surgery and the patient has been free of
tumor recurrence or metastasis for 25 months.
Pathological findings of the surgical specimen
Macroscopically, the tumor mass, which was buried
mostly in the renal parenchyma and displayed endophylic
growth, was situated in the lower pole of the left kidney,
as shown on USG and CT images. The resected margins
of the tumor mass were clear. There was no invasion into
the renal capsule, perinephric fat tissues, and the renal
parenchyma adjacent to the mass. The excised section of
the tumor was gray to white in color and firm upon palpa-
tion. Necrosis and hemorrhage were absent on gross in-
spection (Fig. 2).
Microscopically, the tumor was composed of spindle-
shape cells distributed variably in the dense collagenous
stroma (so-called “patternless pattern”) and had a focal
hemangiopericytomatous staghorn-like vascular pattern
(Fig. 3a and b). Mitotic figures and atypical structures
were not identified. There were no necrotic and
hemorrhagic findings in the tumor. In IHC, the tumor
cells were negative for desmin, S-100, c-Kit, CK-AE1/
AE3, EMA, CD31, CD117, CDK4, MDM2 and p63. The
cells were diffusely positive for CD34, CD99, Bcl2,
vimentin, α-smooth muscle actin, NAB2, STAT6, and
GRIA2 (Figs. 3c and 4) [3, 4, 26, 29]. Ki-67 levels were
very low in the tumor nuclei (0.6 to 0.7 %) (Fig. 3d). The
microscopic findings were consistent with classic SFT
without malignant histology as described by previous
studies [7, 19, 8]. PAX8, a marker for renal differentiation,
was also positive diffusely in the tumor nuclei (Fig. 5).
Two cases of pleural SFTs with non-malignant nature,
obtained from the pathological archives in our institu-
tion, were used as positive controls for examining
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reactivity for various antibodies, including NAB2,
STAT6, and GRIA2. One case showed positive staining
for both STAT6 and GRAI2, while the other was
STAT6-negative but GRIA2-positive (data not shown).
The result was similar to a report by Vivero et al. [4].
The former case was positive for NAB2, but the latter
was negative (data not shown).
Paraffin-embedded formalin-fixed specimens used for
routine pathological investigation were available for IHC
of the SFT in the present study. IHC protocols using
various primary antibodies are described elsewhere in
Additional file 1.
Identification of a NAB2-STAT6 gene fusion in the SFT
Fresh frozen tumor specimens resected surgically from
the patient at the Yamagata University Hospital were
used for detection of a NAB2-STAT6 gene fusion by
quantitative reverse transcription-polymerase chain reac-
tion (RT-PCR) and immunoblotting, as reported else-
where [30, 23, 31, 32]. In addition to the SFT mass,
normal renal tissue was compared as a control. PCR
primers were designed with reference to previous papers
[21, 20, 23]. Structures of the primers used in this study
are shown in Additional file 2. In situ proximity ligation
brightfield assay (PLA) was performed for IHC detection
of nuclear NAB2-STAT6 fusion in the SFT using a Duo-
link® kit together with anti-NAB2 and -STAT6 primary
antibodies. A brief description of the methodology of
RT-PCR, direct sequencing and in situ PLA in the
present study is presented in Additional file 1.
The results of RT-PCR and direct sequencing are pre-
sented in Additional file 3 (Additional file 3: Fig. S1) and
Fig. 6, respectively. RT-PCR with various combination of
forward and reverse PCR primers indicates that a NAB2-
STAT6 gene fusion occurred at some point between
exon1 of NAB2 and exon5 of STAT6 (Additional file 3).
Direct sequencing demonstrated that the fusion junction
occurred between NAB2 in exon2, truncated at 831 kb,
and the beginning of STAT6 in exon3 (Fig. 6 and Add-
itional file 4). In addition, an NAB2-STAT6 fusion gene
was identified as red nuclear dots in an in situ PLA assay
of pathological sections of the renal SFT (Fig. 4d).
Discussion
Primary SFTs in the kidney are extremely rare among
previous reports of extrathoracic SFTs [8]. Very recently,
a growing number of papers on SFT have been pub-
lished, describing an NAB2-STAT6 fusion gene in the
tumor [20–22, 24, 33], the diagnostic relevance of
STAT6 or GRIA2 IHC [4, 5, 25, 26], relationships
1 cm 1 cm 1 cm 1 cm 
a b c d
Fig. 1 Clinical images of the left renal tumor. A mass with clear margin and mostly endophylic growth was detected in the lower and posterior
part of the left kidney. a The tumor presented with a non-cystic mass of a heterogeneous nature in ultrasound. Color Doppler imaging showed
hypervascularity in the tumor. b, c, d) Dynamic computed tomography of the left renal tumor. b Image before administration of the contrast
medium. c Early phase of enhanced computed tomography. A blood vessel was visualized in the tumor. d The tumor showed earlier washout of
enhancement than the adjacent normal renal parenchyma
Fig. 2 Cut section of the resected kidney and tumor. Upon gross
inspection, the tumor located in the lower and dorsal part of the left
kidney had expansive growth, was well-demarcated from the renal
parenchyma, and had a whitish color. Neither necrosis nor bleeding
were observed on the cut surface of the tumor
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between fusional variations of the NAB2-STAT6 gene,
histological features and clinical prognosis [23, 24, 30],
and expression profiles of genes other than NAB2-
STAT6 [24, 34]. However, these reports are based on
SFT specimens from case studies that do not include
primary renal SFT or do not describe the specific site of
isolation. Diffuse positivity of PAX8 in the nuclei of the
present SFT may reflect its renal origin (Fig. 5).
Originally introduced by England et al. [19], the
diagnostic criteria for malignant SFT are increased
cellularity, pleomorphism, necrosis and hemorrhage,
and mitotic activities > 4 counts/10 HPFs on micros-
copy [8, 7, 19]. In a retrospective analysis of 83 SFT pa-
tients, including 59 extrathoracic SFTs, who underwent
surgical resection, Wilky et al. reported that malignant
histology was very strongly associated with recurrence,
but that extrathoracic location could also independently
predict recurrence [35]. Therefore, the renal SFT in the
present case may have malignant potential, although it is
considered benign, both microscopically and clinically, as
there has been no distant metastasis or invasion into adja-
cent tissues in a radical nephrectomy, and no recurrence
since the operation. Thus, there is generally no strict cor-
relation between histology and clinical behavior in SFT. It
would be more appropriate to describe SFT without ma-
lignant nature in histological and clinical presentation as
“classic” SFT rather than “benign” SFT.
Renal SFT is presumed to originate from s renal cap-
sule, interstitial or peripelvic connective tissue [7, 8]. Re-
ported in a review [8], the renal capsule is the most
common site of the origins. The renal SFT in the
present report may occur in intrarenal interstitial tissue
because it displayed mostly endophylic growth within
the kidney.
50 µm1 mm
100 µm 200 µm
a: HE b: HE
c: CD34 d: Ki-67
Fig. 3 Microscopy of conventional staining of pathological specimens. The tumor had slit-like vessels (a, arrows) and expansive compression of
the adjacent normal renal tissues (a, arrowheads). The tumor constituted spindle-shaped cells situated in variable directions in dense collagenous
stroma (b) and had diffuse CD34 expression throughout the tumor (c). A small number of tumor nuclei were positive for Ki-67, with a Ki-67
labeling index of 0.6–0.7 % (d, arrow). Mitosis, atypia, necrosis and hemorrhage were not found by microscopy in the tumor (a to d). These
findings about the kidney tumor are consistent with a classic SFT without malignant nature. Original magnification: x20, x400, x200 and x100 for
A, B, C and D, respectively. HE, hematoxylin and eosin
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Recently, Barthelmeß et al. [23] demonstrated that dif-
ferent patterns of the NAB2-STAT6 gene fusion could
cause specific histology and distinct clinical behaviors in
SFT. In their report, twelve different NAB2-STAT6 fu-
sion variants were identified in 48 of 52 study patients.
These were classified by microscopy into three groups,
NAB2 exon4-STAT6 exon2/3 (n = 27), NAB2 exon6-
STAT6 exon16/17 (n = 11), and other patterns (n = 10).
The first group corresponded to classic thoracic SFT
with diffuse fibrosis and non-malignant nature. The sec-
ond group represented SFT from deep soft tissue with
aggressive behavior and poor prognosis. The recurrence
rates in the two groups were 15 % and 64 %, respectively
(p < 0.016) [23]. With a NAB2 exon2 (internal)-STAT6
exon3 fusion, the renal SFT in our case was consistent
with Barthelmeβ et al.’s third group of other variants of
NAB2-STAT6 gene fusions. On average, the third group
had mitotic counts of 1.0/10 HPFs, a tumor diameter of
3.7 cm and classic characters for SFT in microscopic
examination. However, it had a clinical recurrence rate
of 10 % over a mean postoperative follow-up of 7.8 years
[23]. Late recurrence ≥10 years after initial diagnosis can
occur in SFT and some cases can behave aggressively
even in the absence of any primary morphologic
evidence of malignancy [36]. In our case, only two
recurrence-free years with regular medical follow-up
have elapsed since radical nephrectomy. Therefore, long-
term follow-up should be recommended because the
probability of future tumor recurrence in our patient
cannot be definitively excluded. On the other hand, care-
ful attention must be paid when directly extrapolating
their results for the renal SFT in presented here. One
reason caution is required is that their findings were
based on the analysis of SFT samples with non-renal pri-
mary origins. Secondly, NAB2-STAT6 gene fusions were
not necessarily detected in about 10–50 % of patients
with SFT [21, 22, 24, 33], implicating that abnormal fu-








d: I n sit u PLA of 
NAB2-STAT6
Fig. 4 Immunohistochemistry for NAB2 (a), STAT6 (b), and GRIA2 (c). The tumor cells diffusely expressed the antigens. d shows the NAB2-STAT6
gene fusion in the renal SFT cells in an in situ proximity ligation brightfield assay, as represented by red dots (arrows). PLA, proximity ligation
brightfield assay. Original magnification: x200 for a, b and c, and x400 for d, respectively
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sufficient for oncogenesis in SFTs. Currently, variations
of the NAB2-STAT6 gene fusion cannot explain clear re-
lationships in tumorigenesis, the preponderance of the
thoracic origin, or the malignant behavior of SFT.
Differentiation and definitive diagnosis of SFT from
other soft tissue tumors has been regarded as difficult
due to histological similarities [4]. IHC against CD34,
CD99, and Bcl-2 are often used as supportive diagnostic
stains for SFT, and 90–95 %, 70 %, and 20–35 % of SFT
cases are positive, respectively [8, 5]. However, other soft
tissue tumors are also frequently positive for CD34,
CD99, and Bcl-2, rendering these antigens non-specific
for SFT [4]. Dedifferentiated liposarcoma, which shows
the similar morphology to SFT on microscopy, was differ-
entiated because IHC for MDM2 and CDK4 was negative
in the present case [37]. Analysis of IHC on a large num-
ber of sarcomas reported a sensitivity of 95 % and 92 %
and a specificity of 81 % and 95 % for, respectively,
MDM2 and CDK4 for the diagnosis of dedifferentiated
liposarcoma [37]. Based on evidence that a NAB2-STAT6
gene fusion is present in most SFT cases, NAB2 and
STAT6 IHC have recently been reported in 100 % [24, 33]
and 86–100 % [23–26, 29] of SFT cases. Surprisingly, only
2.3–2.5 % of non-SFT soft tissue tumors exhibited positive
and weak reactions in IHC with anti-STAT6 antibodies
[25, 26]. Thus, STAT6 IHC could be a valuable diagnostic
standard for the NAB2-STAT6 fusion protein in SFT
[5, 26, 25]. Vivero et al. demonstrated that GRIA2
was a useful marker for distinguishing SFT from most
mimics, as 89 % of SFTs were GRIA2-positive, while
100 µm
Fig. 5 Immunohistochemistry for PAX8. The PAX8 antigen was expressed diffusely in the nuclei of the tumor cells (with spindle-shape nuclei) and
the renal tubules (with round nuclei, arrow). Original magnification: x200
NAB2, exon 2
STAT6, exon 3 
Fig. 6 Direct sequencing of the NAB2-STAT6 gene fusion. The junction of the gene fusion were found at 831 bp within NAB2 in exon 2 and the
beginning of STAT6 in exon 3
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only 5–10 % of other soft tissue tumors were positive,
except for dermatofibrosarcoma and myoepithelioma
[4]. In their report, a noteworthy case of SFT proven
to have the NAB2-STAT6 gene fusion was STAT6-
negative but GRIA2-positive in IHC.
In normal cells, NAB2 and STAT6 are located close to-
gether on chromosome 12 and transcribed in opposite
directions [26]. STAT6 and NAB2 function antagonistic-
ally as a transcription activator and a repressor, respect-
ively, regulating wound healing and fibrosis via early
growth response 1-mediated pathways [26]. GRIA2, a
glutamate receptor subunit, affects cell membrane cal-
cium permeability, cell proliferation, motility, and cell
death [4]. GRIA2 is normally expressed in the central
nervous system under physiological conditions, but
GRIA2 can be detected in various oncogenic conditions
via unknown mechanisms [4, 22]. In the present study,
the renal SFT, which had a NAB2-STAT6 gene fusion
identified by direct sequencing, was stained positively
with anti-NAB2, -STAT6, and -GRIA2 antibodies in
IHC. However, one pleural SFT, used as a positive IHC
control in the present analysis, was negative for NAB2
and STAT6 in IHC but positive for GRIA2. This finding
of reciprocal staining of STAT6 and GRIA2 in SFT may
lead the future identification of an alternative pathway of
tumorigenesis in SFT. Our findings are based on a renal
SFT and two pleural SFT cases. Similar to remarks from
Kuroda et al. [7], we also think that a broader investiga-
tion will be necessary to clarify the etiology of SFT and
discuss its clinical characteristics and prognosis.
Conclusions
For the first time, we have reported a case of GRIA2-
positive SFT occurring primarily in the kidney with a
NAB2 (exon 2, internal)-STAT6 (exon 3) gene fusion for
the first time. It might present with tumor background
of a renal origin that the tumor cells in the present SFT
expressed diffusely not only STAT6, NAB2 and GRIA2
but also PAX8. Indeed, clinical prognosis cannot be ne-
cessarily predicted by classic/non-malignant histology of
SFT, but analysis of genetic alterations in SFT would
help to ameliorate prognostic prediction of the tumor.
In the present case, long-term follow-up should be per-
formed after radical nephrectomy, as classic SFT from
an extrathoracic origin may have malignant potential.
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